Learn more from Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development, on the progress being made across our GI oncology portfolio at #ESMO26. bit.ly/4yDiOs9

Incyte shared new data from our KRAS G12D and TGFβR2xPD-1 programs in PDAC and MSS CRC at #ESMO26. Learn more. bit.ly/3WMBt7v

Despite advances, pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging cancers to treat. Understanding KRAS G12D mutations is central to advancing more targeted research for these patients. Learn more. #SolveOn bit.ly/4iaUDfX

We’ve announced a clinical trial collaboration with @Genmab for patients with first-line metastatic colorectal cancer (CRC) harboring a KRAS G12D mutation. Learn more. bit.ly/4BpE07x

⏰ #ESMO26 begins tomorrow! We're looking forward to sharing new data from our solid tumor portfolio, including research in pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable colorectal cancer (MSS CRC). Read our press release to learn more. bit.ly/4siy248

At #ESMO26, Incyte will share new data from our oncology portfolio. Learn more. bit.ly/4elWBHL

From our booth to sessions at the #EADVCongress, it was exciting to connect with the global dermatology community and share the latest in inflammation and autoimmunity.

There’s more to vitiligo than what appears on the skin. A deeper understanding of the condition and the experiences of people living with it is essential to continued progress. Learn more about Incyte’s work to address patient needs through science and innovation. bit.ly/4AERnjV

At this year’s #EADVCongress we’ll join researchers, clinicians and advocates from around the world to discuss how a deeper understanding of immune-mediated skin conditions can help advance research and patient care. bit.ly/4xUWYA7

An important milestone for people living with fibrodysplasia ossificans progressiva (FOP). The @FDA has approved an oral ALK2 inhibitor developed by Incyte and licensed to @mirumpharma for worldwide development and commercialization. Learn more in the press release. bit.ly/4rxVfza

Here’s a look at where data from the Incyte portfolio will be throughout this year’s #EADVCongress. We look forward to connecting with the dermatology community and advancing important scientific conversations. bit.ly/4iJuS73

Join us at the upcoming European Academy of Dermatology and Venereology (EADV) Congress where we will share our latest scientific advancements in inflammation and autoimmunity. Learn more about our data. #EADVCongress bit.ly/4dtDsDk

We're attending the @nbd_foundation's 78th Annual Bleeding Disorders Conference (BDC) in Orlando, August 13–15. Our team is excited to listen to, learn from and connect with the bleeding disorders community. #BDC2026

Patients guide our work in dermatology. Hervé Lamarque, Division Vice President, Head of Business Unit Inflammation & Autoimmunity (IAI) International, shares how Incyte’s commitment to the global dermatology community helps shape our research and innovation. bit.ly/44VPJvQ

Atopic dermatitis (AD) is a chronic inflammatory skin disease that can affect daily life. Learn more about AD and our commitment to patients. bit.ly/44VPJvQ

Incyte announces @EU_Commission approval of our topical JAK treatment for adults with moderate atopic dermatitis. Read to learn more. bit.ly/4ftTxul

Read our press release to learn more about Incyte’s Q2 financial results and business updates. bit.ly/4hkgZLZ

We’ll be presenting data from our Oncology pipeline at the @myESMO 2026 Congress in Madrid. Highlights include updates from our KRAS G12D inhibitor in pancreatic cancer and our TGFβR2×PD-1 bispecific antibody in colorectal cancer. Join us at #ESMO26 to explore the data and what’s next across our oncology portfolio. bit.ly/4w8ni9E

We’re focused on building a portfolio of scientifically differentiated compounds designed to make a meaningful impact for patients. Learn more about von Willebrand disease (VWD), the most common inherited bleeding disorder, and the data presented at this year’s #ISTH2026 Congress. bit.ly/4vuZnQU

Data from our Phase 1/2 multidose study in von Willebrand disease (VWD) was presented at the @isth Congress. Learn more about the data. #ISTH2026 bit.ly/4ydqJ0h